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Abstract
Introduction Pregnant women and infants are at risk of
severe influenza and pertussis infection. Inactivated influenza
vaccine (IIV) and diphtheria-tetanus-acellular pertussis
vaccine (dTpa) are recommended during pregnancy to
protect both mothers and infants. In Australia, uptake is
not routinely monitored but coverage appears sub-optimal.
Evidence on the safety of combined antenatal IIV and dTpa is
fragmented or deficient, and there remain knowledge gaps of
population-level vaccine effectiveness. We aim to establish a
large, population-based, multi-jurisdictional cohort of motherinfant pairs to measure the uptake, safety and effectiveness
of antenatal IIV and dTpa vaccines in three Australian
jurisdictions. This is a first step toward assessing the impact
of antenatal vaccination programmes in Australia, which
can then inform government policy with respect to future
strategies in national vaccination programmes.
Methods and analysis ‘Links2HealthierBubs’ is an
observational, population-based, retrospective cohort
study established through probabilistic record linkage
of administrative health data. The cohort includes births
between 2012 and 2017 (~607 605 mother-infant pairs) in
jurisdictions with population-level antenatal vaccination and
health outcome data (Western Australia, Queensland and the
Northern Territory). Perinatal data will be the reference frame
to identify the cohort. Jurisdictional vaccination registers
will identify antenatal vaccination status and the gestational
timing of vaccination. Information on maternal, fetal and child
health outcomes will be obtained from hospitalisation and
emergency department records, notifiable diseases databases,
developmental anomalies databases, birth and mortality
registers.
Ethics and dissemination Ethical approval was obtained
from the Western Australian Department of Health, Curtin
University, the Menzies School of Health Research, the Royal
Brisbane and Women’s Hospital, and the West Australian
Aboriginal Health Ethics Committees. Research findings will be
disseminated in peer-reviewed journals, at scientific meetings,
and may be incorporated into communication materials for
public health agencies and the public.

Strengths and limitations of this study
►► Record linkage allows the generation of a large, rich

population-based dataset from multiple sources at
low cost.
►► Linked data from three jurisdictions will establish a
cohort with sufficient sample size to enable the examination of uncommon or rare outcomes (eg, neonatal mortality), the evaluation of antenatal vaccines
among subgroup populations (eg, infants with risk
factors such as preterm infants, Aboriginal and/or
Torres Strait Islander peoples), and allows follow-up
of mother-infant pairs in the cohort over an extended
period of time.
►► Inclusion of a geographically and socioeconomically
diverse, population-based sample will help to minimise selection bias in the cohort.
►► Analytic techniques will be employed to minimise
potential bias from differential health-seeking behaviour of vaccinated women.
►► As a retrospective, observational cohort study using linked administrative data, vaccination cannot be randomly assigned; however, it allows
whole-of-population assessment and maximises
follow-up of the cohort.

Introduction
Pregnant women, as a result of their changed
immunological status, are particularly susceptible to severe infection. Data from studies
conducted during influenza pandemics have
shown pregnant women to be at elevated
risk of severe influenza infection and its
complications.1 2 Furthermore, the risk of
hospitalisation from influenza or pneumonia
increases progressively throughout the pregnancy.3 4 Deaths among pregnant women and
perinatal mortality in infants born to infected
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With the establishment of the AIR in 2016, the analyses
performed here could be applied to a national dataset
through AIR linkage in future.

Aims
The ‘Links2HealthierBubs’ study combines health information from multiple sources at an individual-level
designed to improve our understanding of the risks and
benefits of antenatal immunisation. We will use existing
record linkage infrastructure to generate a large cohort
of pregnancies and establish a population-based mother-infant cohort sufficiently powered to estimate rare or
uncommon outcomes that have not been possible with
individual state-based data to date to address three aims
(figure 1).
Aim 1: Measure the effectiveness of IIV and dTpa against
laboratory-confirmed infections in pregnant women and their
infants
Although this is a rapidly growing area of research, there
remain several gaps in our knowledge of antenatal vaccination (table 1). First, limited data have been published
evaluating effectiveness against disease severity (such as
hospitalisation).20–23 Few studies have evaluated the influence of gestational timing of influenza vaccine administration on disease prevention in mothers and infants,24–26
or the safety and effectiveness of repeat doses, particularly with regard to the currently recommended pertussis
vaccine that also contain tetanus and diphtheria. The
interval between influenza vaccination and birth is associated with changes in the level of protective antibody
present in newborns.27 Longer intervals between influenza vaccination and delivery, as well as intervals too
close to delivery, have been shown to result in lower cordblood titres in infants, potentially reducing vaccine effectiveness.27 Although known to influence transplacental
antibody transfer, few studies have measured the impact
of these factors on clinical end-points, such as hospitalisation of mothers and infants with respiratory illness.
Second, few studies have evaluated the role that antenatal vaccination may have on the performance of childhood vaccines. Immunological evidence of ‘blunting’ of
infant responses to pertussis vaccines due to interference
by maternal antibodies has been observed.28–30 Finally,
despite the disproportionate burden of respiratory infections among Aboriginal and/or Torres Strait Islander
infants, the effectiveness of vaccination in pregnancy
for this population group has not yet been measured in
Australia. Such data are important for informing future
prevention programmes.
This cohort study aims to address these gaps by:
1. Measuring the effectiveness of antenatal IIV and dTpa
vaccines on laboratory-confirmed influenza and pertussis infections among mothers and their infants in
the first 6 months of life, with subgroup analyses by: (1)
trimester of vaccination and (2) among infants with
risk factors for infection (eg, preterm birth, small for
Sarna M, et al. BMJ Open 2019;9:e030277. doi:10.1136/bmjopen-2019-030277
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women during the 2009 H1N1 influenza pandemic highlighted the disease risk.5
Respiratory infections during critical periods of lung
development and immune maturation are one of the
most common causes of death in early infancy.6 Infants
aged 1–5 months, an age when they are ineligible for
influenza vaccine, have the highest rates of influenza.7 In
Australia, hospitalisation rates of acute lower respiratory
infection among Aboriginal and/or Torres Strait Islander
children are nearly six times that of non-Aboriginal children.8 Influenza and pertussis infections account for one
in every four of these hospital admissions.9
In the absence of a licensed and effective vaccine for
newborns,5 influenza and pertussis vaccination during pregnancy has been recommended as a means to safeguard
newborns during their first few months of life. Randomised
controlled trials suggest that maternal immunisation against
influenza prevents infection in both the mother and their
infant.10 11 Data from the USA and the UK have shown
that vaccination during pregnancy can reduce influenza
by 71% and pertussis by 91% in young infants.12 13 In 2012,
the WHO released a position paper on influenza vaccination recommending that pregnant women should have the
highest priority for countries considering expansion of their
seasonal influenza vaccination programme.14
Inactivated influenza vaccine (IIV) in pregnancy
has been a long-standing policy recommendation in
Australia15 and is offered free of charge funded by the
government. Following the success of maternal vaccination to prevent pertussis in early infancy in the UK,12 low
dose diphtheria-tetanus-acellular pertussis vaccine (dTpa)
became the second vaccine recommended routinely
during pregnancy in Australia in April 2015 and funded
by state and national immunisation programmes.15
Despite the importance to health and significant programmatic costs, Australia currently lacks a coordinated approach
to maternal vaccination. Uptake of routinely recommended
vaccines in pregnancy is suboptimal and not systematically
monitored.16–19 Pregnancy status is not collected as part of
the national whole-of-life immunisation register, the Australian Immunisation Register (AIR), making antenatal immunisation impossible to measure using AIR alone. In Western
Australia (WA), Queensland (QLD) and the Northern
Territory (NT), antenatal immunisation status is routinely
collected via either state-based immunisation registers or
through perinatal data collections. These collections offer
the opportunity to conduct high-quality, population-level
evaluation of the health effects of antenatal vaccination
programmes in these jurisdictions.
The ‘Links2HealthierBubs’ project is a vital first step
toward national evaluation of antenatal vaccination
in Australia. Identification of factors associated with
under-immunisation will enable more targeted vaccine
promotion. Study results will inform antenatal vaccine
programmes and Australian governmental policy.
Improved antenatal vaccination programme monitoring and delivery is essential in reducing influenza and
pertussis-related illness in pregnant women and infants.

Open access

gestational age (SGA) and Aboriginal and/or Torres
Strait Islander infants).
2. Assessing the impact of antenatal pertussis vaccination
on the effectiveness of other childhood vaccines routinely offered on the immunisation schedule by comparing disease notifications in the first 6 months of life
in fully vaccinated infants of mothers who did and did
not receive maternal pertussis vaccination.
Aim 2: Assess the safety of IIV and dTpa given antenatally in
mothers and infants
A number of studies, including several systematic
reviews,31–33 have found no evidence that IIV or dTpa
adversely impacts the fetus; however, there is a dearth
of postimplementation data evaluating the safety of
combined administration of IIV and dTpa during
pregnancy in terms of adverse events for mothers and
differences in birth outcomes following IIV and dTpa
vaccination during pregnancy. Large, comprehensive
datasets are required to compare outcomes such as
preterm birth, birth weight, SGA, birth defects, stillbirth
and neonatal death (<1 month of age) between women
who have received IIV and dTpa during pregnancy and
unvaccinated pregnant women.16 Furthermore, few
studies have evaluated the potential health impact of
antenatal IIV and dTpa administration on the health of
infants beyond 6 months of age.22 34 35
This cohort study will assess the safety of IIV and dTpa
vaccination during pregnancy on:
1. Health outcomes in the perinatal period and early
childhood (up to 5 years), including (but not restricted
Sarna M, et al. BMJ Open 2019;9:e030277. doi:10.1136/bmjopen-2019-030277

to) preterm birth, birth weight, SGA, birth defects and
cerebral palsy, stillbirth, and neonatal death (<1 month
of age).
2. Maternal health, including severe adverse events resulting in hospitalisation or admission to the intensive
care unit (ICU).
Aim 3: Evaluate antenatal vaccine coverage in Australia
A number of studies have identified predictors of antenatal vaccination, including maternal age, pre-existing
medical conditions and socioeconomic status.36 As vaccine
coverage in pregnant women is not routinely monitored in
Australia, the influence of other demographic and health
factors, including geographic variation, is not well understood. Limited data are available by remoteness, geographic
area and level of socioeconomic deprivation.17 37 Moreover,
uptake in Aboriginal and/or Torres Strait Islander mothers
is poorly defined.17 38 Disparities between Aboriginal and
non-Aboriginal children in the childhood immunisation
schedule have shown lower vaccine coverage in the first year
of life in Aboriginal and/or Torres Strait Islander children
compared with non-Aboriginal infants as a result of greater
delay in the receipt of vaccines,39 although these trends may
not be reflected in the uptake of maternal vaccines.
To address this, the ‘Links2HealthierBubs’ cohort study
aims to:
1. Identify geographic, sociodemographic (including by
Aboriginal status) and other risk factors associated with
uptake of IIV and/or dTpa vaccine during pregnancy.
2. Evaluate trends in vaccine uptake among pregnant
women in Australia.
3
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Figure 1 Establishment of study cohort using record linkage: Western Australia (WA), Queensland (QLD), and the Northern
Territory (NT), 2012–2017. *Vaccination records were obtained from state-wide registers in each participating jurisdiction; in WA,
this register was restricted to pregnant women; in the NT and QLD, these registers included all vaccinations administered to
individuals in the state. †Developmental anomaly data available in WA and QLD; primary care data available in NT only.
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Knowledge gap

Component of the Study

AIM 1: Vaccine effectiveness
Few studies have measured the effectiveness of antenatal
influenza and pertussis vaccines in preventing maternal and
infant laboratory-confirmed infection

Measure effectiveness of antenatal IIV and dTpa on laboratoryconfirmed infection in mothers and in the first 6 months of life
in infants

There is limited evidence evaluating whether antenatal
vaccination protects against severe disease in mothers and
infants

Measure effectiveness against hospitalised infection and
infections required admission to intensive care unit

Few studies have been sufficiently powered to assess the
potential influence of gestational timing of vaccination on
vaccine effectiveness

Assess the potential influence of trimester of the effectiveness
of vaccination

No studies have measured the effectiveness of antenatal
vaccination among infants with risk factors for severe disease

Measure effectiveness among infants with risk factors for
infection (ie, preterm infants, Indigenous infants, infants with
developmental anomalies)

Despite clinical evidence suggesting the presence of maternal Assess the potential influence of maternal pertussis
antibodies may inhibit infant response to primary pertussis
immunisation on childhood vaccine effectiveness
vaccination, population-level data evaluating this are limited
AIM 2: Vaccine safety
Limited data exist evaluating the impact of concomitant
administration of influenza and pertussis vaccines

Assess the safety of IIV and dTpa on maternal and infant
health

Few studies have been sufficiently powered to assess safety
end-points by trimester of vaccination

Consider the trimester of vaccination in the assessment of
safety end-points for IIV and dTpa

Few studies have evaluated outcome measures associated
with antenatal vaccination beyond 6 months of age

Assess the impact of IIV and dTpa in terms of neonatal, infant
and child health up to 5 years of age

AIM 3: Vaccine coverage
There are limited data on antenatal uptake of vaccines across Estimate the uptake of IIV and dTpa; IIV only and dTpa only in
multiple jurisdictions in Australia including sub-analyses based the three jurisdictions and special population groups (ie, lowon sociodemographic factors
income, remote, CALD, by maternal country of birth)
Few longitudinal studies exist which have evaluated trends in
vaccine coverage in multiple Australian jurisdictions
No study in Australia has assessed the importance of
residence or performed spatial analyses in relation to maternal
vaccination

Assess trends in vaccine coverage in multiple Australian
jurisdictions using population-level data for both IIV and dTpa
Identify whether there are geographic, regional, and other
sociodemographic predictors of vaccination during pregnancy

CALD: culturally and linguistically diverse; dTpa; diphtheria-tetanus-acellular pertussis vaccine; IIV; inactivated influenza vaccine.

Methods and analysis
Study design and setting
‘Links2HealthierBubs’ is an observational, population-based cohort study using retrospective data collected
in administrative health registers from three jurisdictions
of Australia (WA, QLD and the NT) where antenatal vaccination data are currently available at a population-level
and can be linked to other health information. Together
these three jurisdictions account for 33% of Australia’s
annual birth cohort, of which Aboriginal and/or Torres
Strait Islander births comprise 8.0%, 8.9% and 35.8% of
total births in each jurisdiction, respectively (table 2).40
Infants will be identified through jurisdictional birth or
perinatal registers. All infants born between 1 January
2012 and 31 December 2017 and their mothers will be
included as participants in the study. This time period
was selected as it includes a baseline period when IIV
was available and routinely recommended,18 but prior
to the introduction of funded dTpa (2012–2014) and an
4

intervention period following the introduction of dTpa
in jurisdictions (2015–2017). Within each jurisdiction,
the cohort of mothers and infants will be linked to vaccination and health data, including emergency department
presentation, hospital separations, birth records, notifiable diseases register and mortality data (table 2). With
the exception of antenatal vaccination registers, these
registers are nationally mandated and provide data to the
Australian Institute of Health and Welfare (AIHW), and
the quality of data is considered to be high.41 Data from
developmental anomalies registries and primary care will
also be obtained in jurisdictions where these are available.
Exposure measurement
Individual-level data on antenatal vaccination will be
obtained from jurisdictional perinatal data collections
(QLD: 2015–2017, WA: 2016–2017) and immunisation
registries (NT: 2012–2017, QLD: 2012–2017, WA: 2012–
2016). These data collections have state-wide coverage of
Sarna M, et al. BMJ Open 2019;9:e030277. doi:10.1136/bmjopen-2019-030277
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Table 1 Summary of project aims and knowledge gaps addressed by the Links2HealthierBubs cohort study
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Population profile
 Total number of births*

Western Australia

Queensland

Northern Territory

208 608

375 001

23 996

 Number of births to Aboriginal 16 748 (8.0%)
and/or Torres Strait Islander
women

33 334 (8.9%)

8592 (35.8%)

 Median age of mothers (years) 30.6

30.1

29.0

Estimated maternal vaccine coverage†
  Influenza

31%

31%

31%

  Pertussis

17%

17%

17%

 Both vaccines

9%

9%

9%

WA Antenatal Vaccination
Database‡

Vaccination Information and
Vaccination Administration
System

NT Immunisation Register

Data sources
 
Exposure
  Vaccination

 
Outcomes
 Perinatal outcomes

WA Midwives Notification
QLD Perinatal Data Collection,
System, WA Birth
Registrar General Births
Registrations, WA Register of
Developmental Anomalies

NT Perinatal Trends, NT
Birth Registry

 Respiratory infections

WA Notifiable Infectious
Disease Database, WA
Hospital Morbidity Data
Collection, WA Emergency
Department Data Collection

QLD Notifiable Conditions, QLD
Hospital Admitted Patient Data
Collection, QLD Emergency
Departments

NT, Notifiable Conditions,
NT Inpatient Activity,
Hospital, NT Emergency,
NT Primary Healthcare
Collection

 Other childhood conditions

WA Hospital Morbidity
Data Collection, WA
Emergency Department Data
Collection, WA Register of
Developmental Anomalies
WA Death Registry

QLD Hospital Admitted Patient
Data Collection, Emergency
Department Data Collection,
Congenital Anomalies Linked
File
Registrar General Deaths

NT Inpatient Activity,
Hospital, NT Emergency,
NT Primary Healthcare
Collection

  Deaths

NT Deaths Registry

*Estimated for the years 2012–2017; Data sources: http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3301.02016?OpenDocument.
†R Andrews, personal communication based on FluMum study unpublished data, 2012–2015.
‡Data available for mothers only (no childhood immunisation data available).
NT, Northern Territory; QLD, Queensland; WA, Western Australia.

pregnant women and will be used to provide information
on IIV and dTpa vaccines administered during pregnancy
and either (1) the gestation of the woman at vaccination,
or (2) the date of vaccination, which will be used together
with gestational age and date of birth to extrapolate gestational age at time of vaccination.
In NT and QLD, where there are immunisation registers covering the study period, information on childhood
vaccines will also be obtained, including the vaccine
administered and the date of administration. Whole-oflife immunisation data were not available for linkage in
WA.
Outcome measurement
Pregnancy and birth outcomes
Information on the pregnancy, labour and birth will be
obtained from jurisdictional perinatal data collections,
Sarna M, et al. BMJ Open 2019;9:e030277. doi:10.1136/bmjopen-2019-030277

hospital separation and emergency department data.
Such information will include complications diagnosed
during pregnancy, episodes of care during pregnancy,
onset of labour and the method of delivery. International
Statistical Classification of Diseases and Related Health
Problems, Tenth Revision, Australian Modification
(ICD-10-AM) codes will be used to obtain conditions from
hospital separation and emergency department data.
Health outcomes at birth include preterm birth
(birth <37 weeks), low birth weight (<2500 g), SGA
(lowest 10th percentile of birth weight for gestation) and
stillbirth (fetal death ≥20 weeks). The variables needed
to measure these outcomes have >95% accuracy.42 Other
available information will include date of birth, APGAR
scores, measures of head circumference and body length,
and days of specialised newborn care required.
5
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Mortality
We will use death registrations from all three jurisdictions
to identify deaths occurring among mothers and infants
in the cohort during the neonatal period. Death registrations provide the date and cause of death for participants
in the cohort.
Developmental anomalies: WA and QLD
Developmental anomalies will be assessed using information in the WA Register of Developmental Anomalies (WARDA) and the Congenital Anomaly Linked File
(CALF) register in QLD. These state-wide registers maintain all diagnosed developmental anomalies for children
up to the age of 5 years, using the same classification categories.43 Only the WARDA is legislated by WA state law.
The WARDA and CALF registers include diagnostic information for up to 10 developmental anomalies, the former
coded using the British Paediatric Association International Classification of Diseases version 9 (BPA-ICD-9),
and the latter using the ICD-10-AM coding system.
Measurement of covariates and risk factors
Information on potential confounders and factors
required for subgroup analysis will be obtained from
jurisdictional perinatal data collections and birth registers. These data collections include information on the
mother’s residence at the time of delivery, which can be
used to determine her geographical location and the
proximity to immunisation services. The mother’s residence will also be used to determine her socioeconomic
level based on Socioeconomic Indexes for Areas, a collection of four indices developed by the Australian Bureau
of Statistics. For this analysis, we will use the Index of
Relative Advantage and Disadvantage at the area level of
collector’s district, the smallest level available for population-wide analyses.44 The mother’s Indigenous status will
be determined based on the Indigenous status recorded
in all available health records. As Indigenous status is
6

not always accurately captured in health data collections in WA and QLD, an algorithm developed in WA
which uses all available health records will be applied to
make a determination of whether the mother is likely to
be Indigenous.45 Indigenous status is considered to be
highly accurate (>99%) for mothers and infants in the
NT, and is based on national best practice guidelines for
data linkage activities relating to Aboriginal and Torres
Strait Islander people, developed by the AIHW and methodology developed in the NT for defining Indigeneity.46
The mother’s medical history will be obtained using lookback through hospital separations data 1 year prior to
conception, as well as medical information recorded in
the perinatal data collection.
Record linkage
Individual information from each dataset will be linked
using jurisdictional record linkage services. Record
linkage uses identifiable demographic data to probabilistically link an individual’s clinical data from different
data repositories. Deidentified datasets with a unique
linkage key for each individual will be provided to the
researchers for analysis. In WA, the Data Linkage Branch
of the Department of Health47 will establish the study
cohort and extract and link relevant data sources. In the
NT, extraction and linkage will be led by SA-NT DataLink,48 and in QLD by the Statistical Services Branch at
QLD Health.49
Power calculation
Cohort data will be aggregated to permit pooled, multi-jurisdictional analyses. We anticipate the total cohort of
~607 605 mother-infant pairs from three jurisdictions will
include ~208 608 pregnancies from WA, 375 001 from
QLD and 23 996 from the NT (table 2).
The number of mother-infant pairs required for influenza and pertussis-related outcomes, and adverse fetal and
neonatal outcomes, under consideration with different
observed vaccine coverage (for α=0.05 and β=0.80) are
listed in table 3. Based on the anticipated total cohort size
and expected vaccine coverage, the overall study will be
powered to detect at least 30% effectiveness against the
majority of infection-related end-points, with the exception of ICU admission for influenza (45%). For most safety
end-points, the anticipated cohort size will be powered to
detect a 10% increase in the approximated relative risk
for vaccinated compared with unvaccinated mothers and
infants, with the exception of stillbirth (15%) and infant
mortality (20%) (table 3).
Data analysis strategy
Using vaccination records, we will measure vaccination status and gestational timing of vaccination in the
cohort. Among the ~607 605 women to be included in
the study cohort, we anticipate ~30% will be vaccinated
against influenza and <5% against pertussis during the
2012–2015 time period; ~35% will be vaccinated against
influenza only, ~60% against pertussis only and ~30%
Sarna M, et al. BMJ Open 2019;9:e030277. doi:10.1136/bmjopen-2019-030277
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Healthcare utilisation and severity of illness
Laboratory-confirmed influenza and pertussis infections
in the first 6 months of life will be identified through the
notifiable diseases databases in each jurisdiction, based
on medical and laboratory notifications made to respective departments of health. The date of notification and
laboratory testing result will be used to determine the
age of the infant and gestation of mothers at the time of
infection.
Hospital separations and emergency department data
from each jurisdiction will be used to identify presentations and admissions to hospital for infants and children
in the cohort. Length of stay in hospital, admission to
ICU and requirement for mechanical ventilation will also
be available from these records.
Access to the NT Primary Care Database will provide
information on episodes of community clinic presentations for mothers and their children in the NT cohort,
including reasons for and the date of the visit.

Open access

Aim

Outcome (estimated incidence)

1

Laboratory-confirmed influenza (1%)
Laboratory-confirmed pertussis infection
(0.5%)

2

Relative
risk

Observed vaccine coverage
10%

15%

20%

25%

1.30
1.30

105 370
211 930

74 827
150 494

59 975
120 630

51 472
103 528

30%
46 216
92 959

Hospitalised influenza (0.3%)

1.30

354 000

251 381

201 500

172 940

155 285

Hospitalised pertussis (0.4%)

1.30

265 210

188 328

150 955

129 556

116 332

Influenza-associated ICU admission (0.1%)

1.45

493 720

351 635

282 655

243 248

218 984

Pertussis-associated ICU admission (0.2%)

1.30

531 600

377 495

302 590

259 700

233 191

Stillbirth (0.7%)

1.15

577 410

408 802

326 725

279 624

250 384

Preterm birth (9%)

1.10

90 850

64 247

51 290

43 844

39 216

Small-for-gestational age (10%)

1.10

80 830

57 160

45 630

39 008

34 889

Birth defects (5%)
Infant mortality (0.4%)

1.10
1.20

96 555
328 340

82 548
281 272

73 839
252 101

171 000
579 100

120 934
410 415

ICU, intensive care unit.

for both vaccines from 2015 onwards.16 Three separate
comparisons will be made: IIV-vaccinated versus unvaccinated, dTpa-vaccinated versus unvaccinated and IIV/
dTpa-vaccinated versus unvaccinated. Cox proportional
hazard models will be used to approximate the relative
risk (hazard ratio, HR) of adverse birth outcomes in vaccinated and unvaccinated mothers and infants. For assessment of birth outcomes, these models will incorporate
the timing of vaccination into exposure assessment in
order to minimise immortal time bias, similar to previous
analyses conducted.50 Gestational/post-conceptional age
will be the time axis. The interval between vaccination
and birth will also be included as an interaction term in
the model.
Vaccine effectiveness of antenatal IIV and dTpa vaccines
on laboratory-confirmed influenza and pertussis infections among mothers and their infants will be calculated
as 1-HR. To minimise confounding in the study results,
we plan to consider inverse probability of treatment
weighting and propensity score matching approaches
into analyses, where appropriate. Propensity scores will
be calculated which will estimate each mother’s individual probability of vaccination. Stratified models will
be used to estimate vaccine effectiveness for sub-groups
(ie, by trimester of vaccination, Aboriginal and/or Torres
Strait Islander infants, preterm infants).
Data management
To facilitate secure data-sharing and analysis of a pooled
dataset across the three sites, information transfer
between SA-NT DataLink, Curtin University, and the
Menzies School of Health Research in Queensland will
be facilitated through secure transfer using the SUFEX
system using AES 128-bit encryption. Safety and security measures are in place at these locations (restricted
staff access, password protection, firewall, virus spyware
protection).
Sarna M, et al. BMJ Open 2019;9:e030277. doi:10.1136/bmjopen-2019-030277

Patient and public involvement
As this is a retrospective study of deidentified, linked
data, patients cannot be involved in the design, recruitment, or conduct of the study. Consumer and community
input into the project will be regularly sought by the WA
Healthy Pregnancies Reference Group at Curtin University. Research findings will be incorporated into communication materials for the community in participating
jurisdictions.

Ethics and dissemination
In Australia, health legislation is state-based and
protected by state-based privacy laws. Appropriate ethics
committee approvals have been sought. As this research
project involves or may impact on Aboriginal and/or
Torres Strait Islander people, particularly in the NT,
ethics approval has also been sought from state-based
Aboriginal ethics committees. Approval has been granted
from the Western Australian Department of Health
(HREC 2016/56), Curtin University (HRE2017-0808),
the Menzies School of Health Research (HREC 20183199), and the Royal Brisbane and Women’s Hospital
(HREC/2018/QRBW/47660) Human Research Ethics
Committees, and the West Australian Aboriginal Health
Ethics Committee (HREC 889). Approval from all data
custodians has also been received.
Results will be disseminated to relevant stakeholders
within each participating state and territory. Research
findings will be published in peer-reviewed journals and
presented at scientific meetings.
Author affiliations
1
School of Public Health, Curtin University, Perth, Western Australia, Australia
2
Menzies School of Health Research, Charles Darwin University, Darwin, Northern
Territory, Australia

7

BMJ Open: first published as 10.1136/bmjopen-2019-030277 on 20 June 2019. Downloaded from http://bmjopen.bmj.com/ on 17 July 2019 by guest. Protected by copyright.
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